These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28408527)

  • 1. The Future of Radioligand Therapy: α, β, or Both?
    Haberkorn U; Giesel F; Morgenstern A; Kratochwil C
    J Nucl Med; 2017 Jul; 58(7):1017-1018. PubMed ID: 28408527
    [No Abstract]   [Full Text] [Related]  

  • 2. The best radionuclide for radioimmunotherapy of small tumors: beta- or alpha-emitter?
    Barbet J; Chatal JF
    Eur J Nucl Med Mol Imaging; 2011 Feb; 38(2):271-3. PubMed ID: 21161707
    [No Abstract]   [Full Text] [Related]  

  • 3. More α Than β for Prostate Cancer?
    Fendler WP; Cutler C
    J Nucl Med; 2017 Nov; 58(11):1709-1710. PubMed ID: 28935836
    [No Abstract]   [Full Text] [Related]  

  • 4. Ac-225 and her daughters: the many faces of Shiva.
    McDevitt MR; Scheinberg DA
    Cell Death Differ; 2002 Jun; 9(6):593-4. PubMed ID: 12032666
    [No Abstract]   [Full Text] [Related]  

  • 5. Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials.
    Marcu L; Bezak E; Allen BJ
    Crit Rev Oncol Hematol; 2018 Mar; 123():7-20. PubMed ID: 29482781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Radiometals Beyond
    Müller C; van der Meulen NP; Benešová M; Schibli R
    J Nucl Med; 2017 Sep; 58(Suppl 2):91S-96S. PubMed ID: 28864619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
    Wild D; Frischknecht M; Zhang H; Morgenstern A; Bruchertseifer F; Boisclair J; Provencher-Bolliger A; Reubi JC; Maecke HR
    Cancer Res; 2011 Feb; 71(3):1009-18. PubMed ID: 21245097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β- radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative.
    Müller C; Zhernosekov K; Köster U; Johnston K; Dorrer H; Hohn A; van der Walt NT; Türler A; Schibli R
    J Nucl Med; 2012 Dec; 53(12):1951-9. PubMed ID: 23139086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 2.
    Poty S; Francesconi LC; McDevitt MR; Morris MJ; Lewis JS
    J Nucl Med; 2018 Jul; 59(7):1020-1027. PubMed ID: 29496984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.
    Kratochwil C; Bruchertseifer F; Giesel FL; Weis M; Verburg FA; Mottaghy F; Kopka K; Apostolidis C; Haberkorn U; Morgenstern A
    J Nucl Med; 2016 Dec; 57(12):1941-1944. PubMed ID: 27390158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Alpha-radioimmunotherapy: a review of recent developments].
    Supiot S; Thillays F; Rio E; Mahé MA; Barbet FJ; Kraeber-Bodéré F; Chérel M
    Cancer Radiother; 2007 Sep; 11(5):252-9. PubMed ID: 17604673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiolanthanides in nuclear medicine.
    Rösch F; Forssell-Aronsson E
    Met Ions Biol Syst; 2004; 42():77-108. PubMed ID: 15206100
    [No Abstract]   [Full Text] [Related]  

  • 13. Beta radiation.
    Welsh JS
    Oncologist; 2006 Feb; 11(2):181-3. PubMed ID: 16476838
    [No Abstract]   [Full Text] [Related]  

  • 14. Alpha particle therapy poised to become new line of cancer treatment.
    Kotz D
    J Nucl Med; 1998 Feb; 39(2):17N-19N, 36N. PubMed ID: 9476918
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential and pitfalls of therapy with alpha-particles.
    Welch MJ
    J Nucl Med; 2005 Aug; 46(8):1254-5. PubMed ID: 16085579
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical estimation of α/β values for prostate cancer from isoeffective phase III randomized trials with moderately hypofractionated radiotherapy.
    Datta NR; Stutz E; Rogers S; Bodis S
    Acta Oncol; 2018 Jul; 57(7):883-894. PubMed ID: 29405785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy.
    Martinez AA; Gonzalez J; Ye H; Ghilezan M; Shetty S; Kernen K; Gustafson G; Krauss D; Vicini F; Kestin L
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):363-70. PubMed ID: 21195875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Envisaging an alpha therapy programme in the atomic energy establishments: the priorities and the nuances.
    Basu S; Banerjee S
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1244-1246. PubMed ID: 28364163
    [No Abstract]   [Full Text] [Related]  

  • 19. Radionuclide therapy of cancer: particle range and therapeutic effectiveness.
    Wheldon TE
    Nucl Med Commun; 1993 Jun; 14(6):408-10. PubMed ID: 8321481
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter from the Editors.
    Sathekge MM; Bouchelouche K
    Semin Nucl Med; 2020 Mar; 50(2):115-117. PubMed ID: 32172794
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.